Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AbbVie’s Business Development, Cancer Plans Not Put Off By Stemcentrx Disappointments

Executive Summary

At J.P. Morgan, AbbVie said the clinical struggles of Rova-T won’t alter its deal-making plans and leave it with plenty of solid tumor possibilities. The pharma took a $4bn write-off of the Stemcentrx deal on Jan. 4.

Advertisement

Related Content

Q4 Pharma Earnings Preview: J&J, Bristol And AbbVie
Deal Watch: Denali Partners With Sirion To Take On The Blood-Brain Barrier
Tizona Lands AbbVie Cancer R&D Deal As New CEO Takes Control
Keeping Track: US FDA Receives Submissions Galore As Year Ends
AbbVie's Rova-T Disappoints As Second-Line SCLC Trial Halted
Weak Rova-T Data May Imperil AbbVie's Larger Cancer Ambitions
Was Rova-T Worth The High Price To AbbVie?

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC124471

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel